LIFE

aTyr Pharma, Inc. is a biotherapeutics company engaged in the discovery and development of medicines from its tRNA synthetase platform. The Company’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. The Company’s primary focus is efzofitimod, a clinical-stage product candidate, which targets neuropilin-2 (NRP2) to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a mechanism of action for potentially treating lung inflammation and fibrosis. Its lead indication for efzofitimod is pulmonary sarcoidosis, a major form of interstitial lung disease. Its other product candidates include ATYR2810, NRP2 mAbs, AARS and DARS. ATYR2810 is a product candidate from its NRP2 antibody program. It is also advancing its preclinical pipeline of tRNA synthetases and NRP2. It has also advanced its preclinical pipeline of NRP2 targeting antibody candidates.